Progetto Laser, lotta alla sepsi in Emilia-Romagna - apicella

Progetto LaSER. Lotta alla sepsi in Emilia-Romagna
Allegati
• Iba T., Kidokoro A. [Activated protein C (the impact of PROWESS trial)]. Nippon Rinsho,
62 (12): 2296-2300, Dec 2004. Japanese. PMID: 15597799 [PubMed - indexed for
MEDLINE]
• Kalil A.C., Coyle S.M., Um J.Y., LaRosa S.P., Turlo M.A., Calvano S.E., Sundin D.P.,
Nelson D.R., Lowry S.F. Effects of drotrecogin alfa (activated) in human endotoxemia.
Shock, 21 (3): 222-229, Mar 2004. PMID: 14770034 [PubMed - indexed for MEDLINE]
• Kinasewitz G.T., Yan S.B., Basson B., Comp P., Russell J.A., Cariou A., Um S.L.,
Utterback B., Laterre P.F., Dhainaut J.F., PROWESS Sepsis Study Group. Universal
changes in biomarkers of coagulation and inflammation occur in patients with severe
sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care, 8 (2): R82-
R90, Apr 2004. Epub 10 Feb 2004. PMID: 15025782 [PubMed - indexed for MEDLINE]
• LaRosa S.P., Opal S.M., Utterback B., Yan S.C., Helterbrand J., Simpson A.J.,
Chaowagul W., White N.J., Fisher C.J. Jr. Decreased protein C, protein S, and
antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by
Burkholderia pseudomallei. Int J Infect Dis, 10 (1): 25-31, Jan 2006. Epub 11 Nov 2005.
PMID: 16290015 [PubMed - indexed for MEDLINE]
• Levy H., Laterre P.F., Bates B., Qualy R.L. Steroid use in PROWESS severe sepsis
patients treated with drotrecogin alfa (activated). Crit Care, 9 (5): R502-R507, 5 Oct
2005b. Epub 27 Jul 2005. PMID: 16277711 [PubMed - indexed for MEDLINE]
• Macias W.L., Vallet B., Bernard G.R., Vincent J.L., Laterre P.F., Nelson D.R., Derchak
P.A., Dhainaut J.F. Sources of variability on the estimate of treatment effect in the
PROWESS trial: implications for the design and conduct of future studies in severe sepsis.
Crit Care Med, 32 (12): 2385-2391, 2004. PMID: 15599140 [PubMed - indexed for
MEDLINE]
• Mamontova O.A., Protsenko D.N., Eliutin D.V., Kirienko P.N., Gel’fand B.R. [Exogenous
activated protein C in severe sepsis]. Anesteziol Reanimatol, 3: 42-45, May-Jun 2005.
Russian. PMID: 16076046 [PubMed - indexed for MEDLINE]
• Nick J.A., Coldren C.D., Geraci M.W., Poch K.R., Fouty B.W., O’Brien J., Gruber M.,
Zarini S., Murphy R.C., Kuhn K., Richter D., Kast K.R., Abraham E. Recombinant human
activated protein C reduces human endotoxin-induced pulmonary inflammation via
inhibition of neutrophil chemotaxis. Blood, 104 (13): 3878-3885, 15 Dec 2004. Epub 31
Aug 2004. Erratum in Blood, 105 (10): 3785, 15 May 2005. PMID: 15339848 [PubMed -
indexed for MEDLINE]
• Oberholzer A., Souza S.M., Tschoeke S.K., Oberholzer C., Abouhamze A., Pribble J.P.,
Moldawer L.L. Plasma cytokine measurements augment prognostic scores as indicators of
outcome in patients with severe sepsis. Shock, 23 (6): 488-493, Jun 2005. PMID:
15897799 [PubMed - indexed for MEDLINE]
• Sacristan J.A., Prieto L., Huete T., Artigas A., Badia X., Chinn C., Hudson P. [Costeffectiveness
of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Gac Sanit, 18 (1): 50-57, Jan-Feb 2004. Spanish. PMID: 14980173 [PubMed - indexed for
MEDLINE]
Dossier 143
98